CD4 and neoplasm: OX40 agonistic monoclonal antibodies in combination with the CD4+ epitope peptide vaccine showed an enhanced peptide-specific CD4+ T cell response, and a slowing of tumour progression in therapeutic models, with an increase in IFN-γ, TNF-ɑ and Granzyme B production (129).